Single cell profiling of tumor-infiltrating immune cells from 32 metastatic melanoma patients treated with anti-PD-1- and/or CTLA-4 antibodies identified two major CD8+ T cell states associated with clinical outcome [50]. This evidence concerns the gene CTLA4 and metastatic melanoma.